

Research article

Open Access

Protective effect of EDTA preadministration on renal ischemia

Chiara Foglieni¹, Alessandro Fulgenzi², Paolo Ticozzi², Fabio Pellegatta³, Clara Sciorati⁴, Daniela Belloni², Elisabetta Ferrero⁴ and Maria Elena Ferrero*²

Address: ¹Cardiovascular Department, Istituto Scientifico San Raffaele, via Olgettina, 60 Milan, Italy, ²Istituto di Patologia Generale, Università degli Studi di Milano, via Mangiagalli 31, Milan, Italy, ³Istituto di Scienze Farmacologiche Università degli Studi di Milano, Via Balzaretti 22, Milan, Italy and ⁴Laboratory of Tumor Immunology, Istituto Scientifico San Raffaele, Via Olgettina 60, Milan, Italy

Email: Chiara Foglieni - foglieni.chiara@hsr.it; Alessandro Fulgenzi - alessandro.fulgenzi@unimi.it; Paolo Ticozzi - paolo.ticozzi@libero.it; Fabio Pellegatta - fabio.pellegatta@unimi.it; Clara Sciorati - sciorati.clara@hsr.it; Daniela Belloni - daniela.belloni@unimi.it; Elisabetta Ferrero - ferrero.elisabetta@hsr.it; Maria Elena Ferrero* - mariaelena.ferrero@unimi.it

* Corresponding author

Published: 15 March 2006

Received: 22 November 2005

BMC Nephrology 2006, 7:5 doi:10.1186/1471-2369-7-5

Accepted: 15 March 2006

This article is available from: <http://www.biomedcentral.com/1471-2369/7/5>

© 2006 Foglieni et al; licensee BioMed Central Ltd.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/2.0>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Background: Chelation therapy with sodium edetate (EDTA) improved renal function and slowed the progression of renal insufficiency in patients subjected to lead intoxication. This study was performed to identify the underlying mechanism of the ability of EDTA treatment to protect kidneys from damage.

Methods: The effects of EDTA administration were studied in a rat model of acute renal failure induced by 60 minutes ischemia followed or not by 60 minutes reperfusion. Renal ischemic damage was evaluated by histological studies and by functional studies, namely serum creatinine and blood urea nitrogen levels. Treatment with EDTA was performed 30 minutes before the induction of ischemia. Polymorphonuclear cell (PMN) adhesion capability, plasmatic nitric oxide (NO) levels and endothelial NO synthase (eNOS) renal expression were studied as well as the EDTA protection from the TNF α -induced vascular leakage in the kidneys. Data was compared by two-way analysis of variance followed by a post hoc test.

Results: EDTA administration resulted in the preservation of both functional and histological parameters of rat kidneys. PMN obtained from peripheral blood of EDTA-treated ischemized rats, displayed a significant reduction in the expression of the adhesion molecule Mac-1 with respect to controls. NO was significantly increased by EDTA administration and eNOS expression was higher and more diffuse in kidneys of rats treated with EDTA than in the controls. Finally, EDTA administration was able to prevent in vivo the TNF α -induced vascular leakage in the kidneys.

Conclusion: This data provides evidence that EDTA treatment is able to protect rat kidneys from ischemic damage possibly through the stimulation of NO production.

Background

Chelation therapy with sodium edetate (EDTA) has been

successfully used to treat chronic lead intoxication [1,2].

More specifically, in patients affected by chronic renal

insufficiency due to environmental lead exposure, EDTA chelation therapy improved renal function and slowed the progression of renal insufficiency [3]. The mechanism by which lead-chelation therapy with EDTA delayed renal damage is unknown. Chelation with another chelating agent, the dimercaptosuccinic acid (DMSA) improved renal function and was efficacious in treating nephropathy [4] and hypertension [5], both induced in animals by long-term exposure to low-levels of lead. It has been proposed that chronic, low-level lead exposure may increase the levels of reactive oxygen species (ROS), responsible for nitric oxide (NO) inactivation [6]. Indeed, lead-chelation therapy might reduce the levels of ROS, associated to NO inactivation, and thus enhance the availability of vascular NO, potentially improving renal function and reducing hypertension [4-6]. Moreover, a multifunctional antioxidant activity has been shown for an iron chelating agent, the N,N'-bis (2-hydroxybenzyl) ethylenediamine-N,N'-diacetic acid (HBED) [7]. We asked if EDTA treatment in rats was able to reduce the renal damage, when not provoked by lead exposure. Indeed, in the present work we have studied the effect of EDTA treatment in preventing rat kidney acute damage following ischemia (Isc) or ischemia/reperfusion (Isc/R) [8,9].

We assessed the effect of EDTA systemically administered in rats, before the induction of renal Isc or Isc/R. Functional and histological kidney alterations and rat plasmatic levels of NO were evaluated, given that NO availability has been found to be responsible for the increased renal function [4,6]. In addition, being NO able to control leukocyte adhesion [10], we determined the expression of the adhesion molecule Mac-1 (monocyte chemoattractant protein-1) (CD18/CD11b) on polymorphonuclear cells (PMN) isolated from control and EDTA-treated rats. In this context, it has been shown that PMN are able to play an important role as mediators of reperfusion injury [11,12]. Finally, since endothelial NO production is an indicator of well functioning endothelium [10], we have evaluated the effect of EDTA in TNF α -induced vascular leakage in rat kidneys.

Herein we show that a single administration of EDTA results in the preservation of renal function and in the prevention of tissue damage induced by ischemic injury. In addition, we demonstrate that the preventive block of NO synthesis abrogate the protective effect of EDTA against renal ischemic damage.

Methods

The investigation conforms with the *Guide for the Care and Use of Laboratory Animals* published by the US National Institute of Health (NIH publication NO.85-23, revised 1996), according to the animal welfare regulations of the Italian local authorities.

Animals

Male Sprague-Dawley rats weighing about 200 g were used (Charles River Italia, Lecco, Italy) and were allowed water and standard rat chow ad libitum. All the rats were maintained at $22 \pm 1^\circ\text{C}$ with a 12/12 hours light/dark cycle.

Ischemia/Reperfusion (Isc/R) model

The rats were anesthetized with an inhaled anesthesia mixture of halothane 2% (Hoechst, Milano, Italy) and oxygen. They were placed on a temperature-regulated table (38°C) (Ugo Basile, Comerio, Lecco, Italy) to maintain body temperature. Kidney ischemia (Isc) was induced by clamping the right renal artery and the right renal vein for 60 minutes with a microsurgical clamp. In the Isc/R group, at the end of the I period, the vascular clamp was removed and reperfusion of 60 minutes was performed. During the surgical procedure the heart rate and the mean arterial blood pressure (MABP) were monitored.

At the end of Isc or of Isc/R, blood samples were obtained by exsanguination of rats at the aorta bifurcation level and kidneys were collected and processed for different studies. Blood and kidneys from EDTA-treated-not-ischemized rats were collected 90 minutes after EDTA administration (corresponding to 30 minutes EDTA pre-treatment+60 min Isc).

Measurement of mean arterial blood pressure

The right femoral artery was cannulated through a polyethylene catheter and connected to a pressure transducer for the measurement of MABP [15,16]. The data was collected continuously by means of a computer and were calculated at baseline, at the end of EDTA pre-treatment (e.g. 30 minutes after EDTA intravenous injection), at the end of Isc and at the end of postischemic R. In sham-operated rats the values were calculated 90 minutes after EDTA pre-treatment.

EDTA treatment

EDTA (calcium disodium EDTA) (Collalto, Brescia, Italy) used in human therapy was employed [3], and at the same dosage (e.g. 40 mg/kg body weight). The sterile drug solution of 2 g/10 ml was opportunely diluted in physiological saline and administered by left intrafemoral vein slow infusion.

L-NAME treatment

The inhibitor of NO synthases L-NAME [N(omega)-nitro-L-arginine methyl ester], when required, was injected simultaneously with the EDTA through the intrafemoral vein at the dose of 30 mg/kg body weight, 30 minutes before the induction of Isc or Isc/R.

Experimental groups

The rats were randomly allocated to 4 study groups, each composed of 15 rats: group 1, controls; group 2, sham operated: the rats underwent the same surgical procedure, except that the clamp was not applied; group 3, Isc: ischemia was induced for 60 min; group 4, Isc/R: ischemia was induced for 60 min, followed by 60 min reperfusion at room temperature. Other identical 4 groups were studied, in which EDTA treatment was performed. In groups 3 and 4 intrafemoral injection of physiological saline 30 minutes before clamping was performed. The 3 and 4 EDTA-treated groups received a single intravenous injection of EDTA 30 minutes before clamping. In groups 1 and 2 intrafemoral injection of physiological saline or EDTA was performed 90 minutes before kidney removal (= 30 minutes EDTA pre-treatment+60 min Isc).

To take in consideration that EDTA could lead to increase in NO plasmatic levels through increase in eNOS expression, we further performed histological evaluations on two additional groups of rats, to verify whether the eNOS inhibitor L-NAME was able to block the protective effect of EDTA in renal ischemic injury. In such groups the animals were simultaneously treated with EDTA and L-NAME 30 minutes before the induction of Isc (group 5) and 30 minutes before the induction of Isc/R (group 6).

Functional studies

Serum creatinine was measured using a modified Jaffe's reaction, and blood urea nitrogen was measured on the AEROSSET system (Abbott Laboratories, Abbott Park, IL) [17].

Histopathology and immunofluorescence microscopy

Kidneys were excised, decapsulated, dissected into 4 pieces along the major ax, fixed by immersion in 4% paraformaldehyde in Dulbecco's PBS (DPBS) overnight at 4°C, cryo-protected in 10% sucrose in DPBS, then embedded in Tissue-Tek medium and frozen in liquid nitrogen. Cryostat-cut four sections/animal (5 µm thick) were submitted to Hematoxylin/Eosin stain; renal damage was evaluated as tubular epithelial cell necrosis, tubular dilation, protein casts and medullary congestion (18). The alterations were semi-quantitatively graded by a pathologist blind to the nature of the experiments. The grading was performed by the following criteria: - =absent, + = barely present, ++ = moderate, +++ = severe. Expression of eNOS, e.g. the endothelial form of the constitutive NO synthase, was assessed on serial sections, with the use of a specific monoclonal antibody (BD Pharmingen, Franklin Lakes, NJ), followed by a Rabbit-anti-Mouse IgG-AlexaFluor488 (Molecular Probes, Eugene, OR). Observations were performed by using an Eclipse 55i microscope (Nikon, Tokyo, Japan), digital images acquired with DS-

L1 camera and LUCIA G software (all from Nikon) and mounted using AdobePhotoshop CS software.

Cytofluorimetry

The expression of Mac-1 was evaluated by following FACS analysis. Whole blood was incubated with 0.5 µg of FITC-conjugated CD11b monoclonal antibody (clone WT5, isotype mouse IgA, K) (Pharmingen, San Diego, CA) for 20 minutes in ice. After erythrocyte lysis, samples were run on a FACScan (Becton-Dickinson, Mountain View, CA) and gated on PMN parameters. Results are expressed as arbitrary units of mean fluorescence intensity (MFI, a.u.).

Nitrite/Nitrate (NO₂/NO₃) determination

The rats were bled off at the aorta bifurcation level. Blood was collected in the presence of 0.065 mM citric acid (Riedel, Hannover, Germany), 0.085 mM sodium citrate (Farmitalia, Milan, Italy) and 2% glucose monohydrate (Riedel) in the blood: anticoagulant ratio of: 7:1. Samples were obtained from rats immediately after the end of each treatment or surgical procedure.

NO release was determined spectrophotometrically [19] by measuring the nitrate/nitrite (NO₂⁻/NO₃⁻) concentration in plasma samples from arterial non coagulated blood. Briefly, whole blood was centrifuged and plasma samples were collected, incubated for 30 min at 37°C in the presence of 0.2 U/ml *Aspergillus* nitrate reductase (Boehringer-Mannheim, Milan, Italy), 50 mM HEPES buffer (pH 7.4), 5 µM flavin adenine dinucleotide (Sigma Aldrich), and 0.1 mM NADPH (Sigma Aldrich). Then, lactate dehydrogenase (Boehringer Mannheim) and sodium pyruvate (Sigma Aldrich) were added to a final concentration of 10 U/ml and 10 mM, respectively, and the samples were incubated for 10 minutes at 37°. The Griess reagent (Sigma Aldrich) was added to the samples (100 µl), and absorbance was measured at 540 nm after 15 minutes incubation at room temperature. Standard curves with increasing concentrations of sodium nitrate and sodium nitrite were run in parallel.

In vivo permeability assay

The assay was performed as described [20]. Briefly, the exit of albumin from vessels into the parenchyma of rat kidneys was assayed. The dye solution contained 0.4% albumin (Sigma Aldrich) and 0.5% trypan blue (Sigma Aldrich) in saline. Following laparotomy, animals were perfused with 5 ml dye-solution through the right renal artery for 10 minutes. The perfusate was drawn from the right renal vein. The right kidney was washed with saline *in vivo*, removed, weighted, suspended and homogenized in buffered phosphate solution at pH 7.4 (1 g tissue dissolved in 3 ml buffer). In treated animals, after halothane anesthesia, EDTA (40 mg/kg) was injected intravenously (through the femoral vein), followed by rat TNFα (R&D

System, Abingdon, UK) (0.1 ng/g). TNF α and EDTA, alone or together, were injected 30 minutes before kidney dye perfusion.

Tissue extracts were centrifuged, the supernatants recovered and treated with 10% deoxycholic acid (sodium salt monohydrate, Sigma Aldrich) in saline, to remove lipid interference. Dye was evaluated by spectrophotometer analysis (Pye Unicam SP6-550, Cambridge, United Kingdom) at 540 nm.

Statistics

The results are expressed as the mean \pm SEM of 15 animals in each group. They were analyzed using a two way analysis of variance followed by Bonferroni t-test. The results were considered statistically significant when $p < 0.05$.

Results

Systemic hemodynamic data

In the rats studied the heart rate did not vary significantly during the experimental procedure (data not shown). To establish whether EDTA could maintain vascular homeostasis, we measured MABP in both untreated and EDTA-treated rats. EDTA treated rats displayed MABP values lower than those of untreated control and sham operated animals. To note, the increase of MABP due to Isc was significantly prevented by EDTA pre-administration (Table 1).

EDTA administration preserved kidneys from ischemic damage

Rats undergoing either renal Isc, obtained by clamping the right renal artery and the right renal vein for 60 minutes, or Isc followed by 60 minutes reperfusion (Isc/R), obtained by removing the clamp, were evaluated for the levels of serum creatinine and blood urea nitrogen (Fig. 1), two parameters routinely used to assess renal function. Both creatinine and urea had a significant increase after the induction of Isc and Isc/R, clearly indicating an impairment of the renal filter function. Interestingly, the administration of EDTA before Isc and Isc/R, maintained

both parameters at physiological levels (Fig. 1), thus suggesting a protective role of EDTA toward the renal filter capacity.

EDTA administration protected kidney from renal structural alterations

To assess whether EDTA, administered before renal Isc or Isc/R induction, protected kidney not only from functional damage but also from structural alterations, we performed histological evaluations, aimed to determine the presence of tubular epithelial cell necrosis, tubular dilation, protein casts and medullary congestion (Fig. 2). For this, kidneys from treated rats were excised and sections were stained with Hematoxylin/Eosin, to compare their architecture with that of control kidneys (Fig. 2a). Picture relative to kidneys from EDTA-treated rats (Fig. 2b) was similar to that of control kidneys (Fig. 2a): indeed, interstitial spaces were maintained and proximal tubule as well as cortical distal segments were preserved. Kidneys from sham-operated rats did not show evidence of important modifications with respect to the controls (data not shown). Kidneys from rats undergoing Isc (Fig. 2c) showed severe renal lesions, mainly tubular, such as dilation and focal engulfment by protein casts. Glomerular and interstitial hemorrhage were also present. Some tubular cells were necrotic, whereas other appeared vacuolized. This picture worsened when kidneys were obtained from rats submitted to R (60 min) after Isc, displaying (Fig. 2e) tubular cast increase and glomerular hypertrophy. Noteworthy, kidneys from animals pre-treated with EDTA before the induction of Isc, (Fig. 2d) failed to show important renal lesions. EDTA pretreatment preserved also the architecture of kidneys submitted to Isc/R (Fig. 2f). No significant differences were evident by comparing panel d and f of Fig. 2. Pictures related to the ascending thick limb in the kidney medulla displayed interstitial hemorrhage at the end of Isc in control kidneys. On the contrary, interstitial hemorrhage was absent in kidneys from EDTA-treated ischemized rats (data not shown). The semiquantitative analysis of renal damage, which represents the mean features for each group of animals, is summarized in Table 2.

Table 1: Measure of mean arterial blood pressure (MABP) in rats

CONTROLS SHAM	UNTREATMENT (mmHg)		EDTA pre-treatment (mmHg)	
	Before clamping	End Isc or Isc/R	Before clamping	End Isc or Isc/R
		100 \pm 8		85 \pm 3*
		108 \pm 11		93 \pm 2*
Isc	104 \pm 6	130 \pm 5**	90 \pm 2*	98 \pm 7*
Isc/R	105 \pm 6	115 \pm 9	90 \pm 3*	88 \pm 8*

EDTA pre-administration (30 min) is able to avoid the increase of MABP induced by kidney Isc. EDTA administration reduces MABP in controls and in sham-operated rats. Isc = ischemia; Isc/R = ischemia/reperfusion.

* $p < 0.05$ vs. corresponding untreated; ** $p < 0.05$ vs Isc before clamping




Figure 1

Effect of EDTA administration on renal function after Isc and Isc/R. Serum creatinine and blood urea nitrogen levels were measured. Rats that received intravenous injection of EDTA; 30 minutes before Isc or Isc/R induction; showed reduced levels of serum creatinine and blood urea nitrogen as compared with control rats (controls = C); Isc = ischemia; Isc/R = 60 minutes kidney ischemia followed by 60 min reperfusion. *p < 0.05.




Figure 2
Renal morphology. Hematoxylin/Eosin images of differently treated rats. Isc = ischemia; Isc/R = ischemia/reperfusion. Representative cortical areas are shown. Notice the abundance of red blood cells and tubular protein casts in c and e panels in comparison with d and f (original magnification $\times 200$).

Table 2: Histologic evaluations of renal injury

Rat treatment	Tubular necrosis	Tubular dilation	Protein casts	Medullary congestion	Glomerular damages	Interstitial stasis
Controls	-	-	-	-	-	-
Sham-operated	+ *	-	-	-	-	+ *
EDTA	-	-	-	-	-	+
Isc	-	+	+ **	+/++	-	++
EDTA+Isc	-	-	-	-	-	+
Isc/R	+	++	+++	+	-	+
EDTA+Isc/R	+ *	++ *	+ *	-	-	+ *
EDTA+L-NAME+Isc	-	+	+	++	-	++
EDTA+L-NAME+Isc/R	+	++	+++	++	-	+

*Focal; **Big, but focal

- = absent; + = barely present; ++ = moderate; +++ = severe

Semiquantitative analysis of renal damage representative of mean features, obtained for each group of rats.

The use of the eNOS inhibitor L-NAME, simultaneously injected with EDTA before the induction of Isc and Isc/R was able to block the beneficial effects induced by EDTA.

Effect of EDTA on Mac-1 expression by PMN

To investigate a putative mechanism of action of EDTA, we considered its effect on PMN, which are largely involved in the damage associated with Isc/R [11,12].

For this purpose, PMN, isolated from peripheral rat blood, were analyzed for the expression of the pro-adhesive molecule Mac-1 (Fig. 3); the existence of Mac-1 up-regulation is suggestive of PMN activation [21]. Mac-1 expression by PMN obtained from control rats increased significantly after Isc and Isc/R. Following EDTA pretreatment, the increase was significantly impaired in rats submitted to Isc and, at lower extent, to Isc/R.

EDTA administration strongly influenced NO production in vivo and renal eNOS expression

Being the expression of adhesion molecules, the adhesive and migratory pattern of leukocytes finely regulated by NO, both in physiologic and pathologic conditions [10,22-24], we then measured rat NO plasmatic levels.

EDTA pre-treatment significantly increased the levels of circulating NO (Fig. 4) both in control and in ischemic rats. Conversely, post-ischemic reperfusion impaired dramatically the production of NO but was not insensitive to EDTA pre-administration: in fact NO production following Isc/R in EDTA-pre-treated rats was similar to that measured in control rats.

As NO in vascular endothelial cells is synthesized primarily by the endothelial form of the constitutive NO-producing enzyme (eNOS), we examined the possibility that a decrease in NO bioavailability might be related to a change in the rate of expression of eNOS. The renal expression of eNOS (Fig. 5), observed in glomerular and interstitial capillaries, was slightly higher and diffuse in animals treated with EDTA (b), as compared to untreated control rats (a). Induction of short time (60 min) Isc, in control rats, produced a loss in the glomerular eNOS and an increase of its interstitial expression (c). When Isc followed EDTA treatment (d), eNOS expression was prevalently assessed inside glomerular capillaries. Kidney sections obtained following Isc/R in controls showed very low expression of eNOS both at glomerular and interstitial levels (e). Kidney sections from rats treated with EDTA

Table 3: Dye solution retention by rat kidneys

Treatment	µg/g
Controls	163 ± 8.3
+TNFα	456 ± 41.8*
+EDTA	178 ± 7.4
+TNFα+EDTA	298 ± 14.5*§

The table reports the modification of vascular permeability; following in vivo treatment with EDTA and TNFα (see Methods section). The rat right kidney was in vivo perfused with trypan blue solution; washed with saline; removed; homogenized and centrifuged. The supernatants were run on a spectrophotometer at 540 nm wavelength. The data was then expressed as µg dye retained per weight (g) of fresh kidney. Maximum dye retention (dye perfusion without washing) yielded a value of 619 ± 24.7.

*p < 0.05 vs. controls; §p < 0.05 vs. TNFα




Figure 3
Expression of Mac-1 by PMN recovered from rat blood. The data represents the values; expressed as mean fluorescence intensity (MFI) (obtained by subtracting the respective value of negative control from each intensity value). Isc = ischemia; Isc/R = ischemia/reperfusion. *p < 0.05.

before Isc/R (f) displayed fluorescence findings comparable to that of controls (a). The use of L-NAME together with EDTA before the induction of Isc and Isc/R abrogated the increase in eNOS expression due to EDTA treatment alone (data not shown).

EDTA regulated the vascular permeability in vivo

It has been recently demonstrated that eNOS has a critical role in regulating the microcirculatory endothelial barrier function *in vivo* [25]. We investigated whether EDTA influenced the TNF α -induced vascular leakage in kidneys. Vascular leakage values (expressed as μ g dye/g fresh kidney and mean \pm SEM of 8 rats) are reported in Table 2. A significant increase in dye retention has been shown by kidneys of rats treated with TNF α with respect to kidneys of untreated animals (controls). EDTA treatment alone did not alter the endothelial barrier function. The concomi-

tant administration of EDTA and TNF α resulted in the significant reduction of TNF α -induced leakage, indicating the existence of tight links among EDTA-NO-vascular protection.

Discussion

EDTA, used in patients affected by chronic lead intoxication, improved renal function [3]. We investigated whether EDTA exerted its protective effect also toward kidneys affected by Isc or Isc/R. For this purpose, we administered intravenously EDTA 30 min before the induction of renal Isc, obtained by clamping the right renal artery and the right renal vein.

The severe renal injury induced by Isc or Isc/R was assessed both as functional impairment, through the serum creatinine and blood urea nitrogen dosages (Figure




Figure 4
Plasmatic NO levels. They are expressed in μM . Rats that received intravenous injection of EDTA showed increased levels of NO as compared with controls (C). Sham = sham-operated rats. Isc = Ischemia; Isc/R = ischemia/reperfusion. * $p < 0.05$ vs C; ** $p < 0.05$ vs. Isc; *** $p < 0.05$ vs. Isc/R.

1), and as structural alteration of tubules and glomeruli (Fig. 2). It should be noted that EDTA administration was efficient in significantly preserving renal function and in preventing structural alterations and necrotic lesions.

NO plays an important role in regulating vascular tone and improving renal blood flow [26]. We show that circulating levels of NO are increased after EDTA injection, followed or not by Isc or Isc/R (Fig. 4). NO administration could act by scavenging the ROS [6]. Indeed, the improvement of NO induced by EDTA treatment could be responsible for a reduced endothelial damage mediated by ROS. In the present study the increase of circulating NO well correlates with the expression of eNOS in kidneys from EDTA-treated rats, also when Isc or Isc/R occurred. Recent data indicates that the renal protective effects due to ischemic preconditioning are attributable to eNOS-mediated NO production [27]. In fact, it has been found that ischemic preconditioning (e.g. three cycles of 2 minutes Isc followed by 5 minutes reperfusion) was able to protect against the Isc/R-induced acute renal failure [27]. Congru-

ously with the finding that pharmacological inhibition of NO synthesis- or disruption of the eNOS gene- significantly increases blood pressure [10,25], EDTA pretreatment has been demonstrated able to prevent the ischemic increase of MABP (Table 1).

NO modulates leukocyte adhesion in the microcirculation by decreasing the binding of PMN to the adhesion molecules E-selectin and ICAM-1 [22,24]. PMN are involved in the tissue damage due to Isc/R injury: their activation and migration in ischemic tissues is followed by release of lytic enzymes and production of ROS [11,28]. We show that Mac-1 expression, widely considered a sensitive marker of PMN activation [21], is up-regulated in rats submitted to kidney Isc and Isc/R. Treatment with EDTA prevents PMN activation in both ischemized and undergoing postischemic reperfusion rats (Figure 3). The efficacy of EDTA treatment in protecting PMN from activation is possibly mediated by the increase in NO production (Fig. 2), given that NO inhibits the increase of adhesion molecule expression [22,24]. Moreover, it has




Figure 5
Immunofluorescence microscopy of eNOS. Localization of eNOS (green) on differently treated rats (Isc = ischemia; Isc/R = ischemia/reperfusion); arrows pointed to positive glomeruli; and arrowheads to negative. Nuclei were counterstained with DAPI (original magnification $\times 200$).

been shown that during the acute myocardial Isc/R the low level of NO increased PMN adhesion to the endothelium [23].

It is known that NO derived from eNOS is a powerful vasodilator and possesses vasoprotective effects [29]. Here we show that EDTA is able to maintain the expression of eNOS on the glomerular and interstitial capillaries after Isc and Isc/R. Several divalent cations (Mn^{++} , Zn^{++} and Fe^{++}) suppressed eNOS activity in crude cell extracts and intact cells whereas Cu^{++} increased eNOS activation [30]. So, we could argue that the removal of some divalent cations by EDTA may improve eNOS levels. In this context, the in vivo use of a divalent cation, the Cd^{++} , was responsible for decreased NO concentration in rat serum [31]. Some clinical evidences support our results. Recently, chelation therapy with EDTA (also associated with vitamin B) in subjects with coronary artery disease showed a significant NO-related endothelial function improvement [32]. Analogously, iron chelation with deferoxamine infusion in cardiomyopathy patients improved NO-mediated endothelium dependent vasodilation, suggesting that iron availability contributes to impair NO action in atherosclerosis [33]. Moreover, cardiovascular protection obtained by the use of high-dose corticosteroids has been shown to be mediated by non-transcriptional activation of eNOS [34]. The role of eNOS as a trigger and mediator of isoflurane-induced delayed preconditioning in vivo has been recently reported [35].

We propose that EDTA may act through an enhancement of endothelial NO production, as previously reported for corticosteroid [34] and also for desflurane, a preconditioning agent able to protect myocardium against Isc/R injury, by favouring NO release [36].

New data suggests for EDTA the favorable antioxidant mechanism of action previously described for other chelating agents [4,7]. In fact the use of EDTA complexes with metal ions as Fe^{++} and Cu^{++} suppressed superoxide and hydrogen peroxide activity [37]. In addition, recently, Hininger et al. [38] showed the beneficial antioxidant effects of EDTA chelating therapy. Since oxidative stress contributes to the pathogenesis of many diseases, including cardiovascular diseases, the protection exerted by EDTA against ischemic damage could be reconducible also to its antioxidant ability.

Conclusion

The data shows that functional and histological parameters of rat kidneys are preserved from damage due to Isc and Isc/R by EDTA treatment. These results suggest the existence of a tight loop EDTA/eNOS/NO, which on the one hand results in the loss of PMN activation and on the

other hand in the maintenance of the endothelial barrier function.

List of abbreviations used

EDTA Sodium edetate
 NO Nitric oxide
 eNOS Endothelial NO synthase
 Isc Ischemia
 Isc/R Ischemia/reperfusion
 PMN Polymorphonuclear cells
 L-NAME N(omega)-nitro-L-arginine methyl ester
 ROS Reactive oxygen species
 MABP Mean arterial blood pressure
 SEM Standard error of the mean
 NO_2^- Nitrate
 NO_3^- Nitrite
 Mac-1 Monocyte chemoattractant protein-1
 TNF α Tumor necrosis factor

Competing interests

The author(s) declare that they have no competing interests.

Authors' contributions

CF performed histological and immunohistochemical analyses. AF and PT performed animal studies and collected samples. FP measured Mac-1 and performed statistical analyses. CS measured NO_2^-/NO_3^- levels. DB performed spectrophotometrical analyses and measured MABP. EF coordinated the in vitro studies. MEF coordinated the in vivo studies and wrote and edited the manuscript.

Acknowledgements

We thank Dr. Laura Rota Nodari and Alessio Giazson for their assistance in microscopy experiments.

References

1. Sanchez-Fructuoso AI, Prats D, Barrientos A: **Treatment of chronic lead intoxication.** *Ann Intern Med* 1999, **131**:716.
2. Lin JL, Ho HH, Yu CC: **Chelation therapy for patients with elevated body lead burden and progressive renal insufficiency. A randomized, controlled trial.** *Ann Intern Med* 1999, **130**:7-13.

3. Lin JL, Lin-Tan DT, Hsu KH, Yu CC: **Environmental lead exposure and progression of chronic renal diseases in patients without diabetes.** *N Engl J Med* 2003, **348**:277-286.
4. Cohen A, Bergamaschi E, Mutti A: **Experimental model of lead nephropathy II. Effect of removal from lead exposure and chelation treatment with dimercaptosuccinic acid (DMSA).** *Environ Res* 1992, **58**:35-54.
5. Vaziri ND, Liang K, Ding Y: **Increased nitric oxide inactivation by reactive oxygen species in lead-induced hypertension.** *Kidney Int* 1999, **6**:1492-1498.
6. Ding Y, Vaziri ND, Gonick HC: **Lead-induced hypertension II Response to sequential infusions of L-arginine; superoxide dismutase; and nitroprusside.** *Environ Res* 1998, **76**:107-113.
7. Samuni AM, Afeworki M, Stein W, Yordanov AT, DeGraff W, Krishna MC, Mitchell JB, Brechbiel MW: **Multifunctional antioxidant activity of HBED iron chelator.** *Free Radic Biol Med* 2001, **30**:170-177.
8. Bonventre JV: **Mechanisms of ischemic acute renal failure.** *Kidney Int* 1993, **43**:1160-1178.
9. Thadhani R, Pascual M, Bonventre JV: **Acute renal failure.** *N Engl J Med* 1996, **334**:448-460.
10. Moncada S, Higgs A: **The L-Arginine-nitric oxide pathway.** *New Eng J Med* 1993, **329**:2002-2011.
11. Freishlag JA, Hanna D: **Neutrophil (PMN) phagocytosis and chemotaxis after reperfusion injury.** *J Surg Res* 1992, **52**:152-156.
12. Granger DN: **Role of xanthine oxidase and granulocytes in ischemia-reperfusion injury.** *Am J Physiol* 1988, **24**:1269-H1275.
13. Baker JE: **Erythropoietin mimics ischemic preconditioning.** *Vascul Pharmacol* 2005, **42**:233-241.
14. Weber NC, Schlack W: **The concept of anaesthetic-induced cardioprotection. mechanism of action.** *Best Pract Res Clin Anaesthesiol* 2005, **19**:429-443.
15. Isobe H, Okajima K, Uchiba M, Harada N, Okabe H: **Antithrombin prevents endotoxin-induced hypotension by inhibiting the induction of nitric oxide synthase in rats.** *Blood* 2002, **99**:1638-45.
16. Isobe H, Okajima K, Uchiba M, Mizutani A, Harada N, Nagasaki A, Okabe K: **Activated protein C prevents endotoxin-induced hypotension in rats by inhibiting excessive production of nitric oxide.** *Circulation* 2001, **104**:1171-5.
17. Molina A, Ubeda M, Escribese MM, Garcia-Bermejo L, Sancho D, de Lema GP, Liano F, Cabanas C, Sanchez-Madrid F, Mampaso F: **Renal ischemia/reperfusion injury, functional tissue preservation by anti-activated {beta}1 integrin therapy.** *J Am Soc Nephrol* 2005, **16**:374-382.
18. Racusen LC: **Alterations in tubular epithelial cell adhesion and mechanisms of acute renal failure.** *Lab Invest* 1992, **67**:158-165.
19. Green LC, Wagner DA, Glogowski J, Skipper PL, Wishnok JS, Tarmenbeu SR: **Analysis of nitrate; nitrite; and (15N)nitrate in biological fluids.** *Anal Biochem* 1982, **126**:131-138.
20. Ferrero ME: **In vivo vascular leakage assay.** *Methods in Molecular Medicine* 2003, **98**:193-200.
21. Kishimoto TK, Jutila MA, Berg EL, Butcher EC: **Neutrophil Mac-1 and MEL-14 adhesion proteins inversely regulated by chemotactic factors.** *Science* 1989, **245**:1238-1241.
22. Guzik TJ, Korb R, Adamek-Guzik T: **Nitric oxide and superoxide in inflammation and immune regulation.** *J Physiol Pharmacol* 2003, **54**:469-87.
23. Egdell RM, Siminiak T, Sheridan DJ: **Modulation of neutrophil activity by nitric oxide during acute myocardial ischaemia and reperfusion.** *Basic Res Cardiol* 1994, **89**:499-509.
24. Wong D, Prameya R, Dorovini-Zis K, Vincent SR: **Nitric oxide regulates interactions of PMN with human brain microvessel endothelial cells.** *Biochem Biophys Res Commun* 2004, **323**:142-48.
25. Huang PL, Huang Z, Mashimo H, Bloch KD, Moskowitz MA, Bevan JA, Fishman MC: **Hypertension in mice lacking the gene for endothelial nitric oxide synthase.** *Nature* 1995, **377**:239-42.
26. Sneider R, Raff U, Vornberger N, Schmidt M, Freund R, Reber M, Schramm L, Gambayran S, Wanner C, Schmidt HH, Galle J: **L-Arginine counteracts nitric oxide deficiency and improves the recovery phase of ischemic acute renal failure in rats.** *Kidney Int* 2004, **64**:216-25.
27. Yamasawa H, Shimizu S, Inoue T, Takaoka M, Maatsumura Y: **Endothelial nitric oxide contributes to the renal protective effects of ischemic preconditioning.** *J Pharmacol Exp Ther* 2005, **312**:153-59.
28. Takahashi T, Hato F, Yamane T, Fukumasu H, Suzuki K, Ogita S, Nishizawa Y, Kitagawa S: **Activation of human neutrophil by cytokine-activated endothelial cells.** *Circ Res* 2001, **88**:422-29.
29. Li H, Hergert SM, Schafer SC, Brausch I, Yao Y, Huang Q, Mang C, Lehr HA, Forstermann U: **Midostaurin upregulates eNOS gene expression and preserves eNOS function in the microcirculation of the mouse.** *Nitric Oxide* 2005, **12**:231-36.
30. Demura Y, Ameshima S, Ishizaki T, Okamura S, Hayashi T, Matsukawa S, Miyamori I: **The activation of eNOS by copper ion (Cu2+) in human pulmonary arterial endothelial cells (HPAEC).** *Free Radic Biol Med* 1998, **25**:314-20.
31. Martynowicz H, Skoczynska A, Wojakowska A, Turczyn B: **Serum vasoactive agents in rats poisoned with cadmium.** *Int J Occup Med Environ Health* 2004, **17**:479-85.
32. Green DJ, O'Driscoll JG, Maiorana A, Scrimgeour NB, Weerasooriya R, Taylor RR: **Effects of chelation with EDTA and vitamin B therapy on nitric oxide-related endothelial vasodilator function.** *Am J Physiol* 1999, **26**:853-56.
33. Duffy SJ, Biegelsen ES, Holbrook M, Russell JD, Gokce N, Keaney JF Jr, Vita JA: **Iron chelation improves endothelial function in patients with coronary artery disease.** *Circulation* 2001, **103**:2799-2804.
34. Hafezi-Moghadam A, Simoncini T, Yang Z, Limbourg FP, Plumier JC, Rebsamen MC, Hsieh CM, Chui DS, Thomas KL, Prorock AJ, Laubach VE, Moskowitz MA, French BA, Ley K, Liao JK: **Acute cardiovascular protective effects of corticosteroids are mediated by non-transcriptional activation of endothelial nitric oxide synthase.** *Nature Med* 2002, **8**:473-79.
35. Chiari PC, Bienengraeber MW, Weihrauch D, Krolkowski JG, Kersten JR, Wartier DC, Pagel PS: **Role of endothelial nitric oxide synthase as a trigger and mediator of isoflurane-induced delayed preconditioning in rabbit myocardium.** *Anesthesiology* 2005, **103**:74-83.
36. Tsai SK, Lin SM, Huang CH, Hung WC, Chih CL, Huang SS: **Effect of desflurane-induced preconditioning following ischemia-reperfusion on nitric oxide release in rabbits.** *Life Sci* 2004, **76**:651-60.
37. Fisher AE, Maxwell SC, Naughton DP: **Superoxide and hydrogen peroxide suppression by metal ions and their EDTA complexes.** *Biochem Biophys Res Commun* 2004, **316**:48-51.
38. Hininger I, Waters R, Osman M, Garrel C, Fernholz K, Roussel AM, Anderson RA: **Acute prooxidant effects of vitamin C in EDTA chelation therapy and long-term antioxidant benefits of therapy.** *Free Radic Biol Med* 2005, **38**:1565-70.

Pre-publication history

The pre-publication history for this paper can be accessed here:

<http://www.biomedcentral.com/1471-2369/7/5/prepub>

Publish with **BioMed Central** and every scientist can read your work free of charge

"BioMed Central will be the most significant development for disseminating the results of biomedical research in our lifetime."

Sir Paul Nurse, Cancer Research UK

Your research papers will be:

- available free of charge to the entire biomedical community
- peer reviewed and published immediately upon acceptance
- cited in PubMed and archived on PubMed Central
- yours — you keep the copyright

Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp

